Exploring the Role of Long Non-Coding RNAs in Predicting Outcomes for Hepatitis B Patients.

BACKGROUND

Hepatitis B is a significant public health issue worldwide. Long noncoding RNAs (lncRNAs) are pivotal in biological mechanisms. The involvement of lncRNAs in hepatitis Hepatitis B remains incompletely understood. This study sought to explore the potential of certain lncRNAs as diagnostic and prognostic markers in hepatitis B, and their ability to differentiate between clinical disease subgroups.

METHODS

Plasma samples from 204 individuals diagnosed with hepatitis B were meticulously examined for the presence of specific lncRNAs, focusing on those known to be associated with hepatitis B as indicated in the literature. In this study, gene expression levels of 14 lncRNAs were analyzed in three subgroups (chronic, recovered and inactive HBsAg carriers) and compared with those in the healthy control group.

RESULTS

The downregulation of the RN7SL1 and Alpha-280 genes in all patients indicates potential diagnostic lncRNAs. ZFHX2-AS1 expression was consistently lower in all subgroups, while SRA1 showed high expression in recovered hepatitis B patients, indicating that it is a descriptive marker. DLG2-AS2 expression increased in the chronic hepatitis B but decreased in the other groups.

CONCLUSIONS

These findings reveal the prognostic importance of lncRNAs in hepatitis B. The expression levels of ZFHX2-AS1, RN7SL1, PCAT-1, PCA3, SRA1 and Alpha-280 have been identified as crucial biomarkers for the diagnosis of hepatitis B and for distinguishing between its clinical subgroups. A strong association between hepatitis B disease and the gene expression of the DLG2-AS2, HOTTIP, HOTAIRM1, HOXA11-AS, NOS2P3, LINC02665, MEG9, and RNY5 lncRNAs has been suggested.